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Subtype heterogeneity for breast cancer risk factors has been suspected, potentially reflecting 2 
etiological differences and implicating risk prediction. Reports are conflicting regarding 3 
presence of heterogeneity for many exposures.  4 
To examine subtype heterogeneity across known breast cancer risk factors, we conducted a 5 
case-control analysis of 2,632 breast cancers and 15,945 controls in Sweden. Molecular 6 
subtype was predicted from pathology-record derived immunohistochemistry markers by a 7 
classifier trained on PAM50 subtyping. Multinomial logistic regression estimated separate 8 
odds ratios for each subtype by the exposures parity, age at first birth, breastfeeding, 9 
menarche, HRT use, somatotype at age 18, benign breast disease, mammographic density, 10 
polygenic risk score, family history of breast cancer and BRCA mutations.  11 
We found clear subtype heterogeneity for genetic factors and breastfeeding. The polygenic 12 
risk score was associated with risk of all subtypes except for the basal-like (p heterogeneity < 13 
0.0001). Parous women who never breastfed were at higher risk of basal-like subtype (OR 14 
4.17; 95% CI 1.89 to 9.21)  compared to both nulliparous (reference) and breastfeeding 15 
women. Breastfeeding was not associated with risk of HER2-overexpressing type, but 16 
protective for all other subtypes.   17 
The observed heterogeneity in risk of distinct breast cancer subtypes for germline variants 18 
supports heterogeneity in etiology and has implications for their use in risk prediction. The 19 
increased risk of basal-like subtype among women who never breastfed merits more research 20 




Breast cancer is a molecularly diverse disease. At least four subtypes have been robustly 2 
established following gene expression based characterization in the early 2000s1,2. These 3 
subtypes (Luminal A, luminal B, HER2-overexpressing and basal-like) behave differently in 4 
terms of age at onset and prognosis, but the question remains to what extent they also 5 
represent etiologically distinct cancers and differ in risk factors. Recently analysis of recurrent 6 
and metastasizing patient samples has shown that breast cancer can drift in molecular subtype 7 
throughout disease progression 3–6. However, it has repeatedly been shown that in situ cancers 8 
display the full spectrum of molecular subtypes before any signs of invasiveness7–11, pointing 9 
towards early determination of the cancer’s nature. Presence of subtype heterogeneity for 10 
breast cancer risk factors could indicate separate etiology for one or several subtypes of breast 11 
cancer, and would also implicate clinical efforts in risk prediction and prevention.  12 
Studies addressing subtype heterogeneity of risk factors have so far employed various 13 
immunohistochemistry (IHC) marker combinations as proxy for the gene-expression based 14 
classifications, which limits precision of findings. Due to the majority of cases in study 15 
populations being luminal, one could expect known risk factors to be biased towards 16 
predicting luminal breast cancers. A few consistent observations have been made: compared 17 
to the most prevalent subtype luminal A, basal-like breast cancer is associated with younger 18 
age at onset, presence of BRCA1 mutations and recent African heritage3. However, results are 19 
less consistent for lifestyle and reproductive risk factors such as HRT use, parity, age at first 20 
birth, and age at menarche4. Most consistent is a stronger protective effect of breastfeeding on 21 
the basal-like subtype among parous women5-8. Intriguingly, although parity has been 22 
consistently associated with decreased risk of luminal subtypes, results vary from a decreased 23 
to an increased risk of the basal-like subtype4. Very little is known about risk factors for the 24 
luminal B and HER2-overexpressing types, related to difficulties in finding consistent IHC 25 
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proxies to represent them4. Moreover, because the relative proportions of subtypes vary across 1 
ethnicities, genetic variation has been put forward as explaining variation in subtype 2 
incidence9,10 but could also be explained by environmental, lifestyle and reproductive 3 
differences11-14. Germline genetic risk factors beyond BRCA mutations should therefore also 4 
be included in studies of subtype heterogeneity. 5 
We aimed to assess the associations between reproductive, genetic and hormonal exposures 6 
and breast cancer subtypes, addressing subtype heterogeneity of risk factors in a Swedish 7 
material. To improve precision in classification of the outcome, we made use of a subset of 8 
our data where PAM50-subtyping was available and predicted subtype on the full dataset 9 
from these, as well as used a previously established IHC proxy to define subtypes to assess 10 
the robustness of any findings.  11 
Methods	12 
Setting	13 
  This is a case-control study based on two Swedish breast cancer cohorts. Ethical approvals 14 
were granted from the regional ethical vetting board and all participants gave written 15 
informed consent.   16 
Participants	17 
Participants were recruited from the the KARolinska MAmmography Project for Risk 18 
Prediction of Breast Cancer (KARMA)  and Libro-1 study cohorts15-16. KARMA is a 19 
prospective cohort study of 70,877 women with or without breast cancer, recruited in 2011 to 20 
2013 from four mammography units situated in Skåne county and Stockholm conducting both 21 
population-based mammography screening and clinical mammography. Libro1 is a case-only, 22 
population-based cohort consisting of 5,715 women diagnosed with breast cancer in 23 
Stockholm years 2001 to 2008. Women in both studies answered questionnaires, donated 24 
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blood at enrollment, and consented to the retrieval of their mammograms and medical records. 1 
Questionnaires and study material were largely similar for both studies as Libro-1 was the 2 
pilot study of KARMA. 3 
All primary invasive breast cancer cases from both studies diagnosed 2005 to 2015 were 4 
eligible for inclusion (n=4,598). The cutoff at 2005 was chosen as IHC markers HER2 and 5 
Ki67 were not stained for, and thus not available in medical records, prior to this year. 6 
Exclusion criteria were missed information on either of the immunohistochemistry (IHC) 7 
markers ER, PR, HER2 and Ki67 (n=1,265). Controls were randomly selected among breast-8 
cancer free participants of the KARMA study, frequency-matched up to 1:5 to cases on age at 9 
enrollment (controls) to age at diagnosis (cases) in 5-year strata using a greedy nearest 10 
neighbor algorithm without replacement17.  The final study sample consisted of 2,632 breast 11 
cancers and 15,945 controls. For the analysis of the polygenic risk score, all KARMA women 12 
who did not have breast cancer and who had available genotyping (n=5425) were used as 13 
controls.   14 
	Data	on	exposures	15 
   Data on parity, age at first birth, breastfeeding, hormone replacement therapy (HRT) use, 16 
somatotype at age 18, menarche, weight and height at enrollment,BRCA1/2 mutation 17 
carriership, country of birth, education and family history of breast cancer was collected from 18 
web- and paper study questionnaires answered at study enrollment, with all variables 19 
harmonized between the two studies prior to analysis. Recall of HRT use was aided by 20 
pictures of HRT brands dispensed in Sweden. Somatotypes were illustrated by 9 pictograms 21 
in the questionnaires and women were asked which pictogram most resembled them at age 18. 22 
As BRCA mutation status was self-reported and thus more likey to be known for cases, only 23 
data on BRCA status from cases were considered for this study. 24 
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History of benign breast disease (BBD) was obtained from pathology records. Only BBD 1 
diagnoses at least one year prior to breast cancer for cases, or before 2013 for the controls, 2 
were included in analysis. Mammograms were collected from radiology departments and 3 
available for 90% of the study population. Mammographic density (MD) was measured using 4 
an automated method previously described15,22. Image pairs from a reading within 4 years 5 
prior to diagnosis or study enrollment were selected for cases and controls respectively and 6 
absolute MD from the left and right mediolateral oblique view were averaged. Data on SNP 7 
markers was obtained from blood donated by participants at enrollment, which had been 8 
genotyped on a custom Illumina iSelect Array (iCOGS Array)23. Missing genotypes were 9 
imputed using 1000 Genomes (phase I integrated variant set release [v3] in National Center 10 
for Biotechnology Information build 37 [hg19] coordinates). Polygenic risk scores (PRS) 11 
were constructed using 77 breast cancer risk SNPs discovered in large consortia studies. The 12 
score for each patient was calculated by summing the number of alleles for each SNP (0, 1 or 13 
2), weighted by the per-allele odds ratios for the minor alleles reported by Mavvadat et al24. 14 
Two scores were generated, one general score using breast cancer risk odds ratios as weights 15 
and the other score using weights from associations to ER negative breast cancer only. Full 16 
details on the construction of the PRS were described previously25.  17 
Data	on	tumor	characteristics	(cases	only)	18 
Data on molecular markers were retrieved in 2015-2016 from medical and pathology records 19 
at treating hospitals. Percent estrogen receptor (ER) and progesterone receptor (PR) staining 20 
was dichotomized into positive or negative status with a cutoff at >= 10% as positive during 21 
this period. HER2 status was dichotomized into positive or negative according to the Swedish 22 
Society of Pathology’s guidelines18: HER2 was considered negative if protein expression 23 
showed 0 or 1+, or was higher with no confirmed gene amplification by fluorescence in-situ 24 
hybridization (FISH), and positive if FISH showed gene amplification. Proliferation marker 25 
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Ki67 was measured in hotspot regions according to contemporary guidelines18 and reported as 1 
percent staining. Information on tumor invasiveness and prior breast cancer diagnoses was 2 
obtained through merges to the Swedish National Cancer Register19 and the Regional Breast 3 
Cancer Quality Register20 using the unique, Swedish personal identity numbers21.  4 
Outcome	classification	5 
    A random forest algorithm was used to construct a subtype classifier using the caret R 6 
package26 (v. 6.0.58). As part of the Clinical Sequencing of Cancer in Sweden (Clinseq) 7 
project, 237 of the cases had had tumors RNA-sequenced and assigned into PAM-50 8 
molecular subtypes as described previously26.  The algorithm was trained to predict subtype 9 
on the subset of the data with PAM50 subtype information available (‘training data’, n=237).  10 
Binary ER, PR, HER2, continuous Ki67 and age at diagnosis were entered as input and the 11 
algorithm run with 5-times repeated 10-fold cross validation to avoid overfitting. Accuracy 12 
and kappa values were used to select the best performing algorithm. The resulting best 13 
algorithm (hereafter denoted ‘classifier’) then assigned PAM50 subtype to all remaining cases 14 
based on their age, ER,PR, HER2 and Ki67 status.   15 
As a sensitivity analysis, the St Gallen method of using immunohistochemistry markers as a 16 
proxy for gene-expression based subtyping28was used to assign subtype, with a modified 17 
cutoff for Ki67 of 25 % instead of 14% due to the lack of whole-slide % for Ki67. This proxy 18 
defines luminal A as ER+/PR+/HER2- and KI67 low, luminal B as either ER+/PR-/HER2-, or 19 
ER+/PR+/HER2-, KI67 high, or ER+/HER2+/any PR, any KI67. HER2-overexpressing is 20 
defined as ER-/PR -/HER2 +, and basal-like defined as ER-/PR-/HER2- (triple negative).  21 
To assess the performance of our classifier and the St Gallen proxy, we obtained accuracy and 22 
kappa statistics for both methods as compared against gene-expression based PAM50 23 
subtyping, by resampling from the 237 observations with PAM50 data (function “resamples” 24 
from the caret package in R). Resampled values were necessary in order to avoid over-fitted, 25 
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over-optimistic statistics for the classifier which had been trained on the same data. Confusion 1 




    In multivariable regression analysis, breast tumors of different subtypes were considered as 6 
separate outcomes and their respective risks were modelled relative to healthy controls via 7 
multinomial regression. For simplicity, we refer to the resulting relative risk ratios as odds 8 
ratios. Heterogeneity in odds ratios was formally assessed with a global Wald test, testing the 9 
null hypothesis that the risk associated with the exposure was the same across all subtypes. 10 
Additionally, multinomial logistic regression was performed in a case-only design using 11 
luminal A cases as the reference group. For the sake of comparison to subtype-specific odds 12 
ratios, odds ratios comparing all breast cancer cases to controls were obtained using 13 
unconditional logistic regression. All analyses were minimally adjusted for age (matching 14 
variable), education level (<10 years, 10 to 12 years, university, other) and country of birth 15 
(binary, Sweden/other), further covariates were included as potential confounders in the 16 
models based on subject matter knowledge. The sets of covariates included in each of the 17 
fully adjusted models are stated in the respective tables. Only case-only analysis was 18 
performed pertaining to exposure BRCA mutation status.   19 
Exposure	parameterizations	20 
First-degree family history of breast cancer was modelled as a binary variable, defined as 21 
having a mother or sister with breast cancer, yes/no. Continuous variables for polygenic risk 22 
scores were scaled prior to modeling and modelled per 1-standard deviation (SD) increase. 23 
Both PRS’s were additionally modelled as categorical variables, cut into quartiles of the 24 
scores. Parity was modelled as a categorical (0, 1 to 2, >2 children) and continuous variable. 25 
9 
 
Age at first birth was dichotomized into < 30 and >= 30 years of age, restricting analysis to 1 
parous women. Breastfeeding was categorized into 0, >0 to 1.5 years and >1.5 years, after 2 
summarizing the total length of breastfeeding across all children. Breastfeeding was also 3 
assessed as a composite variable including parity, by using nulliparous women as reference 4 
group. HRT use was modelled as ‘Ever’/’Never’ use. Women who reported use of locally 5 
administered HRTexclusively were coded as never users. Somatotype was modelled as a 6 
semi-continuous variable by assigning integers to each somatotype 1-9 from lowest to highest 7 
adiposity. Menarche was modelled per year’s delay as a continuous variable. Mammographic 8 
density was scaled prior to modelling and assessed per-1 SD increase. Benign breast disease 9 
was separated into non-proliferative and proliferative, non-atypical lesions  and modeled as 10 
binary variables of ‘ever’/’never’ diagnosed. Atypical proliferative lesions were not included 11 
in analysis due to insufficient numbers. 12 
 13 
All statistical tests were two-sided with a pre-determined cutoff for statistical significance at 14 
alpha = 0.05. Software R29 v.3.2.2 was used for all statistical analysis.  15 
Results	16 
Outcome	classification	17 
The average resampled accuracy and kappa values were 0.73 and 0.55 for the random forest 18 
classifier, and 0.64 and 0.46 for the St Gallen IHC proxy. For all main tables, the random 19 
forest classifer was used for outcome classification. The mode of IHC marker combinations 20 
for cases classified as luminal A or B was ER+/PR+/HER2-, observed for 80% and 54% 21 
respectively, for HER2-overexpressing ER-/PR-/HER2+, observed for 45%, and for basal-like 22 
triple negative for all markers, observed for 85%. Average percentage Ki67 staining was 14% 23 
among luminal A tumors, 46% among luminal B tumors, 36% among HER2-overexpressing 24 
tumors and 69% among basal-like tumors (Table 1). Confusion matrixes of true vs. predicted 25 
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subtypes revealed that both the classifier and the St Gallen IHC proxy were good at capturing 1 
luminal A and basal-like status, but performed worse for luminal B and HER2-overexpressing 2 
tumors (Supplementary Table 1). 3 
Descriptive	cross-tabulations	4 
Table 1 shows crude descriptive contingency tables of cases verses controls, and cases by 5 
subtypes for adjusting variables and selected exposures of interest. Cases tended to be more 6 
highly educated, more often born abroad, had a higher frequency of family history of breast 7 
cancer and had breastfed less than controls. Within subtypes, variations in age, BRCA 8 
mutations and breastfeeding were observed. Although age ranges were similar across 9 
subtypes, luminal A cases were on average older than the other categories (59 years) and 10 
basal-like cases were youngest at diagnosis (52 years) (Table 1).  11 
Adjusted	case-control	odds	ratios	12 
Multivariable regression analysis of genetic background risk factors for each subtype is 13 
shown in Table 2. The general 77-SNP PRS was associated with all subtypes except for the 14 
basal-like subtype, and most strongly associated with the luminal A subtype. The Wald test 15 
showed significant heterogeneity across subtype odds ratios (pheterogeneity <0.0001). In contrast 16 
to the general PRS, the PRS weighted on associations to ER negative breast cancer yielded no 17 
evidence of heterogeneity of effect across subtypes (pheterogeneity = 0.43, Table 2). There was no 18 
evidence of heterogeneity for first-degree family history across breast cancer subtypes (Table 19 
2).  20 
 Multivariable regression analysis of reproductive factors by subtypes is shown in Table 3. 21 
There was no statistical evidence of heterogeneity between subtypes for parity, however 22 
judging from point estimates, parity had a protective effect on all subtypes except for basal-23 
like subtype. Similarly, in analysis of parous women, no heterogeneity was observed for age 24 
at first birth (Table 3). The effects of breastfeeding were heterogeneous across subtypes 25 
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(pheterogeneity = 0.01). With nulliparous women as reference group, parous women who never 1 
breastfed had an increased risk of basal-like breast cancer (OR 4.17;  95 % CI 1.89 to 9.21). 2 
Breastfeeding returned the risk of basal-like breast cancer to that of nulliparous women (OR 3 
breastfeeding <1.5 years 1.02; 95 % CI 0.59 to 1.76), OR breastfeeding >= 1.5 years 0.81; 95 4 
% CI 0.43 to 1.60) (Table 3). In contrast, the risk of developing luminal A breast cancer was 5 
no different from nulliparous women for parous women never breastfeeding (OR 1.01; 95 % 6 
CI 0.74 to 1.39), but a protective effect was seen for breastfeeding (breastfeeding <1.5 years, 7 
OR 0.69; 95 % CI 0.59 to 0.82), breastfeeding >= 1.5 years, OR 0.63; 95 % CI 0.52 to 0.76). 8 
Luminal B showed point estimates similar to those of luminal A, whereas HER 2-9 
overexpressing type was unaffected by breastfeeding (Table 3). 10 
Multivariable analysis of lifestyle and non-reproductive hormonal factors by subtypes is 11 
shown in Table 4. Ever use of hormone replacement therapy (HRT) showed heterogeneity 12 
(pheterogeneity = 0.05), with increased risk for the luminal A (Ever HRT use, OR 1.43, 95 % CI 13 
1.28 to 1.61) but no effect among the other subtypes (Table 4). Point estimates for age at 14 
menarche, somatotype at age 18 and benign breast disease also suggested differences by 15 
subtype but no statistically significant heterogeneity was observed. Still, for age at menarche, 16 
a protective effect of increasing age was observed for the luminal A and B subtypes alone.  17 
Increasingly endomorph somatotype at age 18 was associated with a protective effect for the 18 
luminal and HER2-subtypes whereas basal-like appeared null-associated. Proliferative non-19 
atypical lesions were associated with luminal A cancers but showed similar estimates for 20 
other subtypes except luminal B, whereas non-proliferative lesions were null-associated with 21 
all subtypes except for a possible increase for the HER2-subtype. There was no evidence of 22 
subtype heterogeneity for mammographic density, with an increased risk for all subtypes of 23 
disease with increasing density. (Table 4).  24 
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Summary of findings for risk factors that displayed subtype heterogeneity are shown 1 
graphically as forest plots in figure 1, separately by subtype. Luminal A and B showed very 2 
similar estimates, whereas the basal-like subtype displayed distinct features (Figure 1). 3 
All analyses were repeated within a case-only design with luminal A as reference, yielding the 4 
same conclusions regarding heterogeneity for PRS, breastfeeding and HRT use as the case-5 
control analysis (Supplementary Tables 2-4). Case-only analysis of self-reported BRCA 6 
mutations among cases showed that basal-like tumors had higher prevalence of BRCA 7 
mutations than other subtypes, with an odds ratio of 11.31 (95% CI 5.37 to 23.07) relative to 8 
luminal A tumors (Supplementary Table 2). 9 
Sensitivity	analysis	10 
All findings were replicated albeit attenuated when using the St Gallen IHC proxy to define 11 
subtypes, except for the heterogeneity found for HRT use, which was not observed 12 
(Supplementary Tables 5-7).  13 
Discussion	14 
Analysis of 2,632 breast cancer cases revealed evidence of subtype heterogeneity for three 15 
categories of risk factors: Genetic susceptibility, HRT use and breastfeeding. The 77-SNP 16 
PRS was exclusively associated with risk of non-basal like subtypes, with the largest effect 17 
size for luminal A breast cancers. HRT use was associated with risk of the luminal A subtype 18 
only. Compared to nulliparous women, never breastfeeding was associated with an increased 19 
risk of basal-like breast cancer but not with risk of the other subtypes. Among parous women, 20 
breastfeeding was protective for the luminal A, B and basal-like subtypes but null-associated 21 
with the HER2-overexpressing subtype. Luminal A and B breast cancers were very similar in 22 
associations with most risk factors. 23 
13 
 
Both germline BRCA mutations (Supplementary Table 2) and PRS (Table 2) were 1 
differentially associated with subtypes, suggesting that in addition to the previously observed 2 
heterogeneity for BRCA1 mutations1,2, inherited low-risk variants could also differentially 3 
increase risk of specific breast cancer subtypes. BRCA1 mutations have been shown 4 
experimentally to result in accumulation of undifferentiated luminal progenitor cells30-33, the 5 
suspected cell-of-origin of basal –like breast cancer34,35,  but it is not known how or if low-6 
risk SNP’s could represent an etiological difference between subtypes. Individual SNPs have 7 
been found to be associated with either subtype or ER status36-39, supporting our finding for 8 
the PRS. The ER-negative weighted PRS was associated with basal-like breast cancer in our 9 
study thus showing potential as a complement or replacement to the overall PRS score for 10 
identification of women at risk of this aggressive disease. Collectively, these observations 11 
also indicate a role of germline variants beyond BRCA in distinct etiology of molecular 12 
subtypes which should be further investigated.  13 
Our results confirm previous reports of the largest protective effect of breastfeeding on risk of 14 
basal-like breast cancer5-8. We additionally show that the protective effect for basal-like breast 15 
cancer stems from never-breastfeeding parous women having higher risk of the basal-like 16 
subtype than both nulliparous and breastfeeding women. The reason behind this increased 17 
risk, should it be causal, is not known. As basal-like cancers are thought to originate from 18 
undifferentiated luminal progenitor cells33,34, the association may be related to higher numbers 19 
of progenitor cells in the absence of breastfeeding. Fully differentiated type 4 lobules do not 20 
form until the end of pregnancy and during lactation under the influence of prolactin40, and 21 
prolactin, released throughout lactation41 , has recently been identified as a central promotor 22 
of luminal progenitor cell maturation in vitro42. This hypothesis would agree with 23 
observations of BRCA1 mutations resulting in accumulation of luminal progenitor cells30-24 
33and the high proportion of basal-like breast cancer among BRCA1 mutation carriers.  25 
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Epidemiological studies have additionally shown that BRCA1 carriers who breastfeed are 1 
more protected from developing breast cancer43,44.  However, future studies should definitely 2 
consider possible confounding by lifestyle factors, preferably including data on reasons for 3 
not breastfeeding. The lack of association with breastfeeding for the HER2-overexpressing 4 
subtype distinguishes it from the other subtypes and merits further investigation, preferably 5 
with gene-expression based subtype definitions.  6 
Point estimates for somatotype, menarche, age at first birth, parity and benign breast disease 7 
suggested heterogeneity but were not statistically different. We saw a protective effect of 8 
parity on all subtypes except for a null association of risk of basal-like breast cancer with 9 
parity, after adjusting for age at first birth and breastfeeding. This is in line with some of the 10 
published literature, whereas others have reported increased risks of the basal-like subtype 11 
with increasing parity. Differences may be partly due to underlying variations in prevalence 12 
of breastfeeding.  13 
We found no evidence of subtype heterogeneity for mammographic density, or with ER-14 
negative weighted PRS. These are important messages for prevention efforts using such 15 
exposures in risk prediction, as they would be expected to identify women at risk of breast 16 
cancer independent of subtype. Mammographic density is an especially promising tool to 17 
predict risk, as it is also among the stronger risk factors for the disease. 18 
All results were robust albeit sometimes attenuated in sensitivity analysis using the St Gallen 19 
IHC proxy to define subtypes (Supplementary Tables 5-7). The only exception was seen for 20 
HRT use, which did not display subtype heterogeneity using the St Gallen IHC proxy. Future 21 
studies should ideally address this question using true gene-expression based subtype data, but 22 
our results suggest heterogeneity in subtype risk for HRT use. 23 
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A limitation of our study is that we only had true PAM50 subtype information for 237 of the 1 
cases and predicted subtype for the rest. As the assigned subtypes were largely latent for true 2 
subtype status, model estimates should be interpreted with caution. Although the overall 3 
accuracy of our classifier was higher compared to the St Gallen IHC proxy for defining 4 
subtypes, it still performed poorly in classifying luminal B and HER2 types and our results 5 
should be interpreted in light of this. 6 
The retrospective nature of this study introduces some elements of caution in interpretation. 7 
Cases may recollect exposures differently than controls, but there is little reason to believe 8 
such differences would vary greatly by subtype. Controls were only available from one of the 9 
cohorts, which potentially could introduce bias. Reassuring is that the case-control odds ratios 10 
for generic breast cancer exhibited the expected strengths and directions of associations 11 
.Moreover, case-only analysis yielded the same conclusions regarding heterogeneity as case-12 
control analysis. Strengths of the current work include the large cohort, the use of a subtype 13 
classifier with improved accuracy compared to a previously used IHC-based method, and the 14 
availability of genetic, lifestyle and reproductive exposures comprehensively assessed in the 15 
same study. 16 
In conclusion, both rare and common inherited gene variants displayed subtype heterogeneity 17 
primarily between basal-like and non-basal like subtypes, suggesting separate etiology and 18 
implications for risk prediction. We additionally found subtype heterogeneity by 19 
breastfeeding status. Relative to nulliparous women, women who did not breastfeed 20 
postpartum were exclusively at an increased risk of basal-like breast cancer. Future research is 21 
needed to confirm or refute this finding, subsequently addressing reasons behind the observed 22 
increase in risk of the highly aggressive subtype basal-like breast cancer. Mammographic 23 
density did not display subtype heterogeneity, which is assuring for usage of mammographic 24 
density in risk prediction and prevention. Finally, although we did improve in overall 25 
16 
 
accuracy over available subtype surrogacy classifiers, more work remains to improve on 1 
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Table 1. Demographics and covariates by case status and breast cancer subtype.  
 Controls Cases  Luminal A Luminal B HER2-
overexpressing 
Basal-like  
Age at enrollment, Range 25 - 88 27 - 88  29 - 87 30 - 82 33 - 88 27 - 81  
Mean (SD) 58 (9.7) 61 (10.3)  62 (9.7) 60 (11.5) 59 (10.4) 55 (12.4)  
Age at diagnosis, Range  25 - 84  26 - 84 28 - 79 28 - 82 25 - 78  
Mean (SD)  58 (10.4)  59 (9.9) 57 (11.4) 55 (10.6) 52 (12.3)  
Education         
<10 years 2,437 (15%) 307 (12%)  231 (13%) 31 (12%) 23 (8%) 22 (14%)  
10-12 years 3,926 (25%) 590 (24%)  419 (23%) 54 (22%) 78 (28%) 39 (26%)  
University 6,840 (43%) 1,135 (46%)  811 (45%) 112 (45%) 143 (52%) 69 (45%)  
Other 2,681 (17%) 448 (18%)  341 (19%) 53 (21%) 31 (11%) 23 (15%)  
Country of birth         
Sweden 14,361 (90%) 2,063 (83%)  1,517 (84%) 205 (82%) 224 (81%) 117 (77%)  
Other 1,570 (10%) 429 (17%)  298 (16%) 45 (18%) 50 (19%) 36 (24%)  
Mother or sister with breast 
cancer 
        
No 13,379 (86%) 1,906 (80%)  1,397 (80%) 182 (76%) 211 (80%) 116 (80%)  
Yes 2,083 (14%) 481 (20%)  341 (20%) 57 (24%) 53 (20%) 30 (20%)  
Parous         
Yes 14,008 (88%) 2,086 (84%)  1,521 (84%) 200 (81%) 232 (84%) 133 (86%)  
No 1,931 (12%) 405 (16%)  292 (16%) 48 (19%) 44 (16%) 21 (14%)  
Breastfeda         
Yes 13,583 (97%) 1,981 (96%)  1,444(96%) 192 (96%) 226 (98%) 119 (91%)  
No 367 (3%) 88 (4%)  64 (4%) 8 (4%) 5 (2%) 11 (9%)  
BRCA mutation         
Yes  41 (2%)  17 (1%) 3 (1%) 3 (1%) 18 (15%)  
No  2,047 (98%)  1,505 (99%) 203 (99%) 234 (99%) 105 (85%)  
IHC markers         
Ki67 mean (SD)  22.6 (20.7)  13.5 (10.1) 45.5 (16.9) 35.8 (17.5) 69.3 (17.7)  
ER+ PR+ HER2-  1,668 (64%)  1,372 (80%) 129 (54%) 4 (0%) 0 (0%)  
ER+ PR+ HER2+  111 (4%)  33 (2%) 38 (16%) 31 (12%) 0 (0%)  
ER+ PR- HER2-  392 (15%)  281 (16%) 57 (24%) 1 (<0.5%) 16 (11%)  
ER+ PR- HER2+  69 (3%)  18 (1%) 14 (6%) 31 (12%) 0 (0%)  
ER- PR- HER2+  123 (5%)  0 (0%) 0 (0%) 114 (45%) 3 (2%)  
ER- PR- HER2-  238 (9%)  15 (1%) 0 (0%) 74 (29%) 119 (85%)  
ER- PR+ HER2-  10 (<0.5%)  6 (<0.5%) 0 (0%) 1 (<0.5%) 3 (2%)  
a = Among parous women only 
25 
 
Table 2. Risk of breast cancer, overall and by subtype, by genetic background. Odds ratios with 95% confidence intervals for controls as reference group. Adjusted for born in 
Sweden or not, education level and age. 
  



























Mother or Sister 
with Breast 
Cancer 
No (Ref.) 13,379 (86%) 1,906 (80%) 1.00 (ref) 1,397 (80%) 1.00 (ref) 182 (76%) 1.00 (ref) 211 (80%) 1.00 (ref) 116 (79%) 1.00 (ref)  
 Yes 2,083 (14%) 481 (20%) 1.60 (1.43-1.79) 341 (20%) 1.53 (1.35-1.75) 57 (24%) 1.99 (1.47-2.69) 53 (20%) 1.65 (1.21-2.24) 30 (21%) 1.71 (1.14-2.57) 0.45 
Polygenic Risk 
Score 
1st quartile 1,521 (28%) 288(16%) 0.79 (0.66-0.95) 190 (15%) 0.77 (0.62-0.96) 31 (18%) 0.88 (0.54-1.44) 41 (18%) 0.70 (0.46-1.05) 26 (24%) 1.03 (0.59-1.80) 0.68 
 2
nd  quartile 
(Ref.) 
1,449 (27%) 362 (20%) 1.00 (ref) 244 (19%) 1.00 (ref) 35 (21%) 1.00 (ref) 48 (26%) 1.00 (ref) 25 (23%) 1.00 (ref)  
 3rd  quartile 1326(24%) 477 (27%) 1.49 (1.26-1.76) 334 (26%) 1.56 (1.28-1.89) 51 (30%) 1.63 (1.05-2.53) 63 (28%) 1.21 (0.84-1.75) 29 (27%) 1.28 (0.74-2.20) 0.56 
 4th  quartile 1,129 (21%) 663 (37%) 2.52 (2.14-2.97) 520 (40%) 3.01 (2.50-3.62) 52 (31%) 2.06 (1.32-3.20) 64 (28%) 1.49 (1.03-2.15) 27 (25%) 1.43 (0.82-2.48) 0.0003 
 Linear, per SD 
increase 
  1.61 (1.51-1.71)  1.74 (1.63-1.87)  1.43 (1.62-1.28)  1.36 (1.18-1.55)  1.15 (0.94-1.40) <0.0001 
Polygenic Risk 
Score 
Weighted on ER -  




1,392(26%) 413 (23%) 1.00 (ref) 303 (24%) 1.00 (ref) 37 (22%) 1.00 (ref) 53 (24%) 1.00 (ref) 20 (19%) 1.00 (ref)  
 3rd quartile 1,336 (25%) 467 (26%) 1.19 (1.01-1.41) 337 (26%) 1.17 (0.97-1.41) 41 (24%) 1.17 (0.74-1.84) 57 (25%) 1.13 (0.77-1.66) 32 (30%) 1.67 (0.95-2.93) 0.68 
 4th quartile 1,244 (23%) 553 (31%) 1.53 (1.30-1.78) 391 (30%) 1.47 (1.23-1.76) 50 (30%) 1.54 (0.99-2.39) 76 (34%) 1.62 (1.13-2.33) 36 (34%) 2.03 (1.17-3.53) 0.71 
 Linear, per SD 
increase 





Table 3. Risk of breast cancer overall and by subtype, by reproductive risk factors. Odds ratios with 95% confidence intervals, for controls as reference group. 
 




OR  (95% CI) 
Any breast cancer 
Luminal A 
(n, %) 




















Nulliparous (ref) 1,931 (12%) 405 (16%) 1.00 (ref) 292 (16%) 1.00 (ref) 48 (19%) 1.00 (ref) 44 (16%) 1.00 (ref) 21 (14%) 1.00 (ref)  
 1-2 children 10,094 (63%) 1,532 (62%) 0.68 (0.60-0.79) 1,118 (62%) 0.68 (0.58-0.80) 142 (57%) 0.56 (0.38-0.82) 173 (63%) 0.70 (0.48-1.04) 99 (64%) 0.97 (0.57-1.66) 0.42 
 >2 children
 
 3,914(25%) 554 (22%) 0.63 (0.55-0.74) 403 (22%) 0.62 (0.52-0.74) 58 (23%) 0.61 (0.40-0.92) 59 (21%) 0.61 (0.40-0.94) 34 (22%) 0.95 (0.63-1.58) 0.58 
 Linear, per child 
increase  
  <0.0001  <0.0001  0.12  0.04  0.6  
Age at first birthb, 
parous women 
only 
<30 (ref) 9,851 (74%) 1,436 (71%) 1.00 (ref) 1,078 (72%) 1.00 (ref) 138 (69%) 1.00 (ref) 158 (68%) 1.00 (ref) 89 (68%) 1.00 (ref)  




Ever (ref) 13,583 (97%) 1,981 (96%) 1.00 (ref) 1,444 (96%) 1.00 (ref) 192 (96%) 1.00 (ref) 226 (98%) 1.00 (ref) 119 (92%) 1.00 (ref)  




Nulliparous (ref) 1,931(12%) 405 (16%) 1.00 (ref) 292 (16%) 1.00 (ref) 48 (19%) 1.00 (ref) 44 (16%) 1.00 (ref) 21 (14%) 1.00 (ref)  
 Parous, never 
breastfed  
 
367 (2%) 88 (4%) 1.09 (0.82-1.43) 64 (4%) 1.01 (0.74-1.39) 8 (3%) 0.95 (0.43-2.09) 5 (1%) 0.64 (0.24-1.67) 11 (7%) 4.17 (1.89–9.21) 0.005 
 Parous, breastfed 
>0-1.5 years  
9,148 (58%) 1,406 (57%) 0.70 (0.61-0.80) 1,039 (57%) 0.69 (0.59-0.82) 128 (52%) 0.55 (0.37-0.81) 157 (57%) 0.72 (0.49-1.07) 82 (54%) 1.02 (0.59-1.76) 0.33 
 Parous, breastfed 
>1.5 years  
4,435 (28%) 575 (23%) 0.63 (0.54-0.75) 405 (25%) 0.63 (0.52-0.76) 64 (26%) 0.59 (0.37-0.95) 69 (25%) 0.64 (0.40-1.02) 37 (25%) 0.81 (0.43-1.60) 0.87 
a = Parity adjusted for born in Sweden or not, age, education level, breastfeeding, age at first birth and BMI. 
b = Age at first birth adjusted for born in Sweden or not, age, education level, breastfeeding, parity and BMI. 
c = Breastfeeding adjusted for born in Sweden or not, age, education level, parity, age at first birth and BMI.  
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Table 4. Risk for breast cancer overall and by subtype: Ever hormone replacement therapy (HRT use), age at menarche, somatotype at age 18, mammographic 
density, benign breast disease (BBD). Odds ratios with 95% confidence intervals, for controls as reference group. SD = standard deviation.  


















g (n, %) 









HRT usea Never 10,922 (75%) 1,414 (66%) 1.00 (ref) 972 (62%) 1.00 (ref) 162 (74%) 1.00 (ref) 172 (70%) 1.00 (ref) 108 (79%) 1.00 (ref)  
 Ever 3,703 (25%) 743 (34%) 1.33 (1.20-1.48) 587 (38%) 1.43 (1.28-1.61) 56 (26%) 0.96 (0.69-1.33) 72 (30%) 1.19 (0.89-1.62) 28 (29%) 1.01 (0.64-1.57) 0.05 
Menarchea Linear, per year 
increase 




Linear, per SD 
increase 
14,814 1,666 1.69 (1.62-1.78) 1,240 1.71 (1.62-1.80) 160 1.71 (1.52-1.93) 171 1.65 (1.42-1.86) 95 1.58 (1.34-1.87) 0.80 









No 14,922 (94%) 2,461 (94%) 1.00 (ref) 1,792 (94%) 1.00 (ref) 248 (94%) 1.00 (ref) 262 (91%) 1.00 (ref) 159 (96%) 1.00 (ref)  
 Yes 1,023 (6%) 171 (6%) 0.99 (0.83-1.18) 122 (6%) 0.93 (0.76-1.13) 17 (6%) 1.11 (0.67-1.82) 25 (9%) 1.48 (0.98-
2.26) 




No 15,566 (98%) 2,544 (97%) 1.00 (ref) 1,847 (97%) 1.00 (ref) 259 (98%) 1.00 (ref) 278 (97%) 1.00 (ref) 160 (96%) 1.00 (ref)  
 Yes 379 (2%) 88 (3%) 1.56 (1.22-1.98) 67 (3%) 1.67 (1.27-2.19) 6 (2%) 1.09 (0.48-2.47) 9 (3%) 1.44 (0.73-
2.82) 
6 (4%) 1.40 (0.57-3.44) 0.77 
a = Adjusted for born in Sweden or not, age, education level, parity and BMI.  
b
 
= Adjusted for born in Sweden or not, age, age at menarche and education level.  




Figure legend  
Figure 1. Forest plots summarizing observed heterogeneity of results for exposures breastfeeding, PRS and HRT use across the subtypes. OR = 
Odds ratio. BF = Breastfeeding. PRS = Polygenic risk score. Q1-4 = Quartiles 1 to 4 of the PRS. HRT = Hormone replacement therapy. 
 
 
